Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.

Mori T, Tajima K, Hirama M, Sato T, Kido K, Iwakami S, Sasaki S, Iwase A, Shiomi K, Maeda M, Hino O, Takahashi K.

J Thorac Dis. 2013 Apr;5(2):145-8. doi: 10.3978/j.issn.2072-1439.2013.03.03.

2.

ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma.

Tajima K, Hirama M, Shiomi K, Ishiwata T, Yoshioka M, Iwase A, Iwakami S, Yamazaki M, Toba M, Tobino K, Sugano K, Ichikawa M, Hagiwara Y, Takahashi K, Hino O.

Anticancer Res. 2008 Nov-Dec;28(6B):3933-6.

3.

Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.

Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, Izumi H, Masuda K, Hirabayashi M, Moroboshi T, Yoshiyama T, Ishida A, Natori Y, Inoue A, Kobayashi M, Sakao Y, Miyamoto H, Takahashi K, Hino O.

Clin Cancer Res. 2008 Mar 1;14(5):1431-7. doi: 10.1158/1078-0432.CCR-07-1613.

4.

Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.

Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.

Clin Cancer Res. 2007 May 15;13(10):2928-35.

5.

Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.

Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T.

J Thorac Oncol. 2008 Nov;3(11):1317-24. doi: 10.1097/JTO.0b013e318187491c.

6.

Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Mundt F, Nilsonne G, Arslan S, Csürös K, Hillerdal G, Yildirim H, Metintas M, Dobra K, Hjerpe A.

PLoS One. 2013 Aug 21;8(8):e72030. doi: 10.1371/journal.pone.0072030. eCollection 2013.

7.

The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma.

Saeki H, Hashizume A, Izumi H, Suzuki F, Ishi K, Nojima M, Maeda M, Hino O.

Oncol Lett. 2012 Oct;4(4):637-641. Epub 2012 Jul 11.

8.

Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?

Sharif S, Zahid I, Routledge T, Scarci M.

Interact Cardiovasc Thorac Surg. 2011 May;12(5):806-11. doi: 10.1510/icvts.2010.255901. Epub 2011 Jan 25. Review.

PMID:
21266493
9.

A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.

Nowak AK, Millward MJ, Creaney J, Francis RJ, Dick IM, Hasani A, van der Schaaf A, Segal A, Musk AW, Byrne MJ.

J Thorac Oncol. 2012 Sep;7(9):1449-56. doi: 10.1097/JTO.0b013e31825f22ee.

10.

Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.

Hagiwara Y, Hamada Y, Kuwahara M, Maeda M, Segawa T, Ishikawa K, Hino O.

Cancer Sci. 2008 Apr;99(4):666-70. doi: 10.1111/j.1349-7006.2008.00731.x. Epub 2008 Feb 24.

11.

Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.

Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Takahashi K, Masuda K, Sakao Y, Hino O.

Cancer Sci. 2006 Sep;97(9):928-32. Epub 2006 Jun 7.

12.

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.

de Fonseka D, Arnold DT, Stadon L, Morley A, Keenan E, Darby M, Armstrong L, Virgo P, Maskell NA.

BMC Cancer. 2018 Feb 17;18(1):199. doi: 10.1186/s12885-018-4113-3.

13.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.

Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272.

PMID:
18154821
14.

Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.

Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T.

Clin Chem Lab Med. 2011 Oct;49(10):1721-6. doi: 10.1515/CCLM.2011.242. Epub 2011 Jun 22.

PMID:
21692685
15.

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.

Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Mutti L, O'Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA.

Eur J Cancer. 2012 Nov;48(16):2983-92. doi: 10.1016/j.ejca.2012.05.018. Epub 2012 Jun 15.

PMID:
22704893
16.

Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma.

Xia H, Karasawa K, Hanyu N, Chang TC, Okamoto M, Kiguchi Y, Kawakami M, Itazawa T.

Int J Hyperthermia. 2006 Nov;22(7):613-21.

PMID:
17079218
17.

The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.

Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N.

Indian J Cancer. 2014 Mar;51 Suppl 3:e82-5. doi: 10.4103/0019-509X.154058.

18.

The established and future biomarkers of malignant pleural mesothelioma.

Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, Røe OD.

Cancer Treat Rev. 2015 Jun;41(6):486-95. doi: 10.1016/j.ctrv.2015.05.001. Epub 2015 May 8. Review.

PMID:
25979846
19.

Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.

Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):646-50. doi: 10.1158/1055-9965.EPI-08-0422. Epub 2009 Feb 3.

20.

Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.

Hasan B, Greillier L, Pallis A, Menis J, Gaafar R, Sylvester R, Fennell DA, Baas P, Surmont V, Van Meerbeeck JP, O'brien ME.

Eur J Cancer. 2014 Nov;50(16):2771-82. doi: 10.1016/j.ejca.2014.07.020. Epub 2014 Aug 21.

PMID:
25155251

Supplemental Content

Support Center